 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug ALENDRONATE SODIUM: The FDA label for Alendronate Sodium does not specify information regarding the risk of angioedema associated with its use. Therefore, it is not possible to[0m
[34mdetermine from this source whether Alendronate Sodium increases or decreases the risk of angioedema.[0m

[34m DO-NOT-KNOW[0m

[34mThe justification for this answer is that the FDA label data, as provided by FDAHandler, does not contain information about the effect of Alendronate Sodium on the risk of angioedema. Without this [0m
[34mspecific information, it is not possible to provide a reliable answer to the question of whether Alendronate Sodium increases or decreases the risk of angioedema.[0m
[1;34m2[0m[34m. Drug ALENDRONATE: ALENDRONATE increases the risk of angioedema. This is based on the information provided by FDAHandler, which cited the ALENDRONATE label indicating that hypersensitivity reactions[0m
[34mincluding urticaria and angioedema have been reported.[0m
[34m                ---------[0m
[34m                Does the alendronate category of drugs increase the risk of[0m
[34m                angioedema, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the alendronate category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The FDA label for Alendronate Sodium does not specify information regarding the risk of angioedema, making it impossible to determine its effect from this source."[0m[32m,[0m
[32m      [0m[32m"The FDAHandler indicates that Alendronate increases the risk of angioedema, as hypersensitivity reactions including urticaria and angioedema have been reported."[0m[32m,[0m
[32m      [0m[32m"Since Alendronate Sodium and Alendronate belong to the same category of drugs and there is a report of increased risk of angioedema for Alendronate, it is reasonable to infer that the category [0m
[32mas a whole may have this risk associated with it, despite the lack of specific information for Alendronate Sodium."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The alendronate category of drugs increases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the alendronate category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The FDA label for Alendronate Sodium does not specify information regarding the risk of angioedema, making it impossible to determine its effect from this source."[0m[34m,[0m
[34m      [0m[34m"The FDAHandler indicates that Alendronate increases the risk of angioedema, as hypersensitivity reactions including urticaria and angioedema have been reported."[0m[34m,[0m
[34m      [0m[34m"Since Alendronate Sodium and Alendronate belong to the same category of drugs and there is a report of increased risk of angioedema for Alendronate, it is reasonable to infer that the category [0m
[34mas a whole may have this risk associated with it, despite the lack of specific information for Alendronate Sodium."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The alendronate category of drugs increases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the alendronate category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The FDA label for Alendronate Sodium does not specify information regarding the risk of angioedema, making it impossible to determine its effect from this source.[0m
[1;31m2[0m[31m. The FDAHandler indicates that Alendronate increases the risk of angioedema, as hypersensitivity reactions including urticaria and angioedema have been reported.[0m
[1;31m3[0m[31m. Since Alendronate Sodium and Alendronate belong to the same category of drugs and there is a report of increased risk of angioedema for Alendronate, it is reasonable to infer that the category as a[0m
[31mwhole may have this risk associated with it, despite the lack of specific information for Alendronate Sodium.[0m
[31m        -----[0m
[31m        Final answer: The alendronate category of drugs increases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is flawed because it contradicts itself. Initially, it is stated that the FDA label for Alendronate Sodium does not specify information regarding the risk of [0m
[32mangioedema, suggesting that there is no evidence to determine its effect. However, the reasoning then shifts to stating that the FDAHandler indicates an increased risk of angioedema for Alendronate. [0m
[32mIf the FDAHandler, which is considered a reliable source, indicates an increased risk, then the initial statement that there is no information to determine the effect is incorrect. The final [0m
[32mconclusion that the alendronate category of drugs increases the risk of angioedema should be based on the information provided by the FDAHandler, and the initial statement should be disregarded as it [0m
[32mis inconsistent with the subsequent evidence provided."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is flawed because it contradicts itself. Initially, it is stated that the FDA label for Alendronate Sodium does not specify information regarding the risk of [0m
[34mangioedema, suggesting that there is no evidence to determine its effect. However, the reasoning then shifts to stating that the FDAHandler indicates an increased risk of angioedema for Alendronate. [0m
[34mIf the FDAHandler, which is considered a reliable source, indicates an increased risk, then the initial statement that there is no information to determine the effect is incorrect. The final [0m
[34mconclusion that the alendronate category of drugs increases the risk of angioedema should be based on the information provided by the FDAHandler, and the initial statement should be disregarded as it [0m
[34mis inconsistent with the subsequent evidence provided."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is flawed because it contradicts itself. Initially, it is stated that the FDA label for Alendronate Sodium does not specify information regarding the risk of [0m
[31mangioedema, suggesting that there is no evidence to determine its effect. However, the reasoning then shifts to stating that the FDAHandler indicates an increased risk of angioedema for Alendronate. [0m
[31mIf the FDAHandler, which is considered a reliable source, indicates an increased risk, then the initial statement that there is no information to determine the effect is incorrect. The final [0m
[31mconclusion that the alendronate category of drugs increases the risk of angioedema should be based on the information provided by the FDAHandler, and the initial statement should be disregarded as it [0m
[31mis inconsistent with the subsequent evidence provided.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the alendronate category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The FDA label for Alendronate Sodium does not provide information regarding the risk of angioedema, which means there is no evidence from this source to suggest an increase or decrease in [0m
[32mrisk."[0m[32m,[0m
[32m      [0m[32m"The FDAHandler indicates that Alendronate, which is within the same category as Alendronate Sodium, does increase the risk of angioedema as hypersensitivity reactions including urticaria and [0m
[32mangioedema have been reported."[0m[32m,[0m
[32m      [0m[32m"Given that Alendronate is reported to increase the risk of angioedema, and it is within the same drug category as Alendronate Sodium, the category as a whole is considered to potentially have [0m
[32mthis risk, despite the lack of specific information for Alendronate Sodium."[0m[32m,[0m
[32m      [0m[32m"The evidence from FDAHandler for Alendronate is used to infer the risk for the category, as drug categories often share similar side effect profiles."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The alendronate category of drugs increases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the alendronate category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The FDA label for Alendronate Sodium does not provide information regarding the risk of angioedema, which means there is no evidence from this source to suggest an increase or decrease in [0m
[34mrisk."[0m[34m,[0m
[34m      [0m[34m"The FDAHandler indicates that Alendronate, which is within the same category as Alendronate Sodium, does increase the risk of angioedema as hypersensitivity reactions including urticaria and [0m
[34mangioedema have been reported."[0m[34m,[0m
[34m      [0m[34m"Given that Alendronate is reported to increase the risk of angioedema, and it is within the same drug category as Alendronate Sodium, the category as a whole is considered to potentially have [0m
[34mthis risk, despite the lack of specific information for Alendronate Sodium."[0m[34m,[0m
[34m      [0m[34m"The evidence from FDAHandler for Alendronate is used to infer the risk for the category, as drug categories often share similar side effect profiles."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The alendronate category of drugs increases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the alendronate category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The FDA label for Alendronate Sodium does not provide information regarding the risk of angioedema, which means there is no evidence from this source to suggest an increase or decrease in [0m
[31mrisk.[0m
[1;31m2[0m[31m. The FDAHandler indicates that Alendronate, which is within the same category as Alendronate Sodium, does increase the risk of angioedema as hypersensitivity reactions including urticaria and [0m
[31mangioedema have been reported.[0m
[1;31m3[0m[31m. Given that Alendronate is reported to increase the risk of angioedema, and it is within the same drug category as Alendronate Sodium, the category as a whole is considered to potentially have this [0m
[31mrisk, despite the lack of specific information for Alendronate Sodium.[0m
[1;31m4[0m[31m. The evidence from FDAHandler for Alendronate is used to infer the risk for the category, as drug categories often share similar side effect profiles.[0m
[31m        -----[0m
[31m        Final answer: The alendronate category of drugs increases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent and correct. The initial statement that there is no information on the FDA label for Alendronate Sodium regarding angioedema risk is not [0m
[32mcontradictory to the subsequent information provided by the FDAHandler about Alendronate. The reasoning correctly infers that since Alendronate, which is in the same category as Alendronate Sodium, is[0m
[32mreported to increase the risk of angioedema, it is reasonable to conclude that the category as a whole may have this risk. The final answer that the alendronate category of drugs increases the risk of[0m
[32mangioedema is supported by the evidence provided by the FDAHandler."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent and correct. The initial statement that there is no information on the FDA label for Alendronate Sodium regarding angioedema risk is not [0m
[34mcontradictory to the subsequent information provided by the FDAHandler about Alendronate. The reasoning correctly infers that since Alendronate, which is in the same category as Alendronate Sodium, is[0m
[34mreported to increase the risk of angioedema, it is reasonable to conclude that the category as a whole may have this risk. The final answer that the alendronate category of drugs increases the risk of[0m
[34mangioedema is supported by the evidence provided by the FDAHandler."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent and correct. The initial statement that there is no information on the FDA label for Alendronate Sodium regarding angioedema risk is not [0m
[31mcontradictory to the subsequent information provided by the FDAHandler about Alendronate. The reasoning correctly infers that since Alendronate, which is in the same category as Alendronate Sodium, is[0m
[31mreported to increase the risk of angioedema, it is reasonable to conclude that the category as a whole may have this risk. The final answer that the alendronate category of drugs increases the risk of[0m
[31mangioedema is supported by the evidence provided by the FDAHandler.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-angioedema-alendronate[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"increase"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.8[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.01[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"rare"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"The FDAHandler indicates that Alendronate, which is within the same category as Alendronate Sodium, increases the risk of angioedema as hypersensitivity reactions including [0m
[32murticaria and angioedema have been reported. Although there is no specific information for Alendronate Sodium, the inference is made based on the reported risk associated with Alendronate. The [0m
[32mevidence is considered weak because it is based on reported reactions, which may not be systematically studied or quantified. The probability is low because such reactions are generally rare, and the [0m
[32mconfidence reflects the uncertainty due to the lack of direct evidence for Alendronate Sodium."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-alendronate[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
